Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 355

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Prophylactic Treatment of Migraine With an Angiotensin II ReceptorBlocker: A Randomized Controlled Trial

Tronvik, Erling, Stovner, Lars J., Helde, Grethe, Sand, Trond, Bovim, Gunnar·2003·JAMA

Abstract

CONTEXT: There is a paucity of effective, well-tolerated drugs available for migraine prophylaxis. OBJECTIVE: To determine whether treatment with the angiotensin II receptor blocker candesartan is effective as a migraine-prophylactic drug. DESIGN AND SETTING: Randomized, double-blind, placebo-controlled crossover study performed in a Norwegian neurological outpatient clinic from January 2001 to February 2002. PATIENTS: Sixty patients aged 18 to 65 years with 2 to 6 migraine attacks per month were recruited mainly from newspaper advertisements. INTERVENTIONS: A placebo run-in period of 4 weeks was followed by two 12-week treatment periods separated by 4 weeks of placebo washout. Thirty patients were randomly assigned to receive one 16-mg candesartan cilexetil tablet daily in the first treatment period followed by 1 placebo tablet daily in the second period. The remaining 30 received placebo followed by candesartan. MAIN OUTCOME MEASURES: The primary end point was number of days with headache; secondary end points included hours with headache, days with migraine, hours with migraine, headache severity index, level of disability, doses of triptans, doses of analgesics, acceptability of treatment, days of sick leave, and quality-of-life variables on the Short Form 36 questionnaire. RESULTS: In a period of 12 weeks, the mean number of days with headache was 18.5 with placebo vs 13.6 with candesartan (P =.001) in the intention-to-treat analysis (n = 57). Some secondary end points also favored candesartan, including hours with headache (139 vs 95; P<.001), days with migraine (12.6 vs 9.0; P<.001), hours with migraine (92.2 vs 59.4; P<.001), headache severity index (293 vs 191; P<.001), level of disability (20.6 vs 14.1; P<.001) and days of sick leave (3.9 vs 1.4; P =.01), although there were no significant differences in health-related quality of life. The number of candesartan responders (reduction of > or =50% compared with placebo) was 18 (31.6%) of 57 for days with headache and 23 (40.4%) of 57 for days with migraine. Adverse events were similar in the 2 periods. CONCLUSION: In this study, the angiotensin II receptor blocker candesartan provided effective migraine prophylaxis, with a tolerability profile comparable with that of placebo.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/jama.289.1.65

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 21 references

Research works printed but not linked: 5

  1. Phillips, 1998, Migraine as a woman's issue—will research and new treatments help?, JAMA, 280, 1975
  2. Stoukides, 1999, Candesartan cilexetil: an angiotensin II receptor blocker., Ann Pharmacother, 33, 1287, 10.1345/aph.19005 · doi:10.1345/aph.19005
  3. Kirk, 1999, Angiotensin-II receptor antagonists: their place in therapy., Am Fam Physician, 59, 3140
  4. Tanaka, 2001, Effects of candesartan on cough and bronchial hyperresponsives in mildly to moderately hypertensive patients with symptomatic asthma., Circulation, 104, 281, 10.1161/01.CIR.104.3.281 · doi:10.1161/01.cir.104.3.281
  5. Not Available. Challenges for the 21st Century: A Gender Perspective on Nutrition Through the Life Cycle ACC/SCN symposium report, nutrition policy paper 17; November1998:82. Available at: http://acc.unsystem.org/scn/Publications/NPP/npp17.pdf. Accessed May 12, 2002.

Cited by

See all 355

Metadata

Authors
Tronvik, E., Stovner, L. J., Helde, G., Sand, T., & Bovim, G.
Venue
JAMA
Published
2003-01-01
Volume
289
Issue
1
Pages
65
ISSN
  • 0002-9955 (ISSN-L)
  • 0098-7484
OpenAlex
W2007009569
Cited by
355
References
21
FWCI
12.46
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Prophylactic Treatment of Migraine With an Angiotensin II ReceptorBlocker: A Randomized Controlled Trial. https://app.cochat.ai/papers/10.1001/jama.289.1.65
The paper
Tronvik, E., Stovner, L. J., Helde, G., Sand, T., & Bovim, G. (2003). Prophylactic Treatment of Migraine With an Angiotensin II ReceptorBlocker: A Randomized Controlled Trial. JAMA. https://doi.org/10.1001/jama.289.1.65

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.